Valsartan in the treatment of heart attack survivors

Vascular Health and Risk Management

Volumn 2, Issue 2, 2006, Pages 125-138

  Jugdutt, Bodh I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Heart failure; Infarct survivors; Myocardial infarction; Remodeling; Valsartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN; ZOFENOPRIL;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DEATH; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INHIBITION KINETICS; KIDNEY DISEASE; MORBIDITY; MORTALITY; PHYSICAL DISABILITY; POLYPHARMACY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIAC OUTPUT, LOW; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RENIN-ANGIOTENSIN SYSTEM; RESEARCH DESIGN; TETRAZOLES; TREATMENT OUTCOME; VALINE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33744979327     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.2.125     Document Type: Review

References (113)

1. [ACE] ACE Inhibitor Myocardial Infarction Collaborative Group. 1998. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation, 97:2202-12.
2. Aguilar D, Solomon SD, Kober L, et al. 2004. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation, 110:1572-8.
3. Aikawa Y, Rohde L, Plehn J, et al. 2001. Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis. Am Heart J, 141:234-42.
4. [AIRE] The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. 1993. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 342:821-8.
5. Ambrosioni E, Borghi C, Magnani B; The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. 1995. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med, 332:80-5.
6. Baruch L, Anand I, Cohen IS, et al. 1999. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation, 99:2658-64.
7. Benz J, Oshrain C, Henry D, et al. 1997. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol, 37:101-7.
8. Buhler FR, Laragh JH, Baer L, et al. 1972. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med, 287:1209-14.
9. Campbell DJ, Aggarwal A, Esler M, et al. 2001. β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet, 358:1609-10.
10. Campbell DJ, Krum H, Esler MD. 2005. Losartan increases bradykinin levels in hypertensive humans. Circulation, 111:315-20.
11. Carson P, Tognoni G, Cohn JN. 2003. Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail, 9:164-71.
12. Chiolero A, Burnier M. 1998. Pharmacology of valsartan, an angiotensin II receptor antagonist. Expert Opin Investig Drugs, 7:1915-25.
13. Chung O, Csikos T, Unger T. 1999. Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertens, 13(Suppl 1):S11-20.
14. Cohn JN, Anand IS, Latini R, et al; Valsartan Heart Failure Trial Investigators. 2003. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation, 108:1306-9.
15. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. 2001. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 345:1667-75.
16. [CONSENSUS] The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med, 316:1429-35.
17. Corea L, Cardoni O, Fogari R, et al. 1996. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther, 60:341-6.
18. Criscione L, de Gasparo M, Buhlmayer P, et al. 1993. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol, 110:761-71.
19. de Gasparo M, Hess P, Clozel M, et al. 2002. Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats. J Cardiovasc Pharmacol, 40:789-800.
20. de Gasparo M, Levens N. 1998. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol, 82:257-71.
21. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. 2002. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet, 360:752-60.
22. Drexler H. 1994. Endothelial dysfunction in heart failure and potential for reversal by ACE inhibition. Br Heart J, 72(3 Suppl): S11-14.
23. Dzau VJ. 1993. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med, 153:937-42.
24. Dzau VJ. 2001. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension, 37:1047-52.
25. Ferrario CM, Jessup J, Chappell MC, et al. 2005. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation, 111:2605-10.
26. Ferrario CM, Trask AJ, Jessup JA. 2005. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol, 289:H2281-90.
27. Flather MD, Yusuf S, Kober L, et al; ACE-Inhibitor Myocardial Infarction Collaborative Group. 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet, 355:1575-81.
28. [GISSI-3] Gruppo Italiano per to Studio della Sopravvivenza nell'infarto Miocardico. 1994. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 343:1115-22.
29. [GISSI-3] Gruppo Italiano per to Studio della Sopravvivenza nell'Infarto Miocardico. 1996. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction. J Am Coll Cardiol, 27:337-44.
30. Granger CB, McMurray JJ, Yusuf S, et al; CHARM Investigators and Committees. 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 362:772-6.
31. Hamroff G, Katz SD, Mancini D, et al. 1999. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation, 99:990-2.
32. Howes LG, Tran D. 2002. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf, 25:73-6.
33. Ishiyama Y, Gallagher PE, Averill DB, et al. 2004. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension, 43:970-6.
34. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. 1995. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet, 345:669-85.
35. Iwata M, Cowling RT, Gurantz D, et al. 2005. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol, 289:H2356-63.
36. Jong P, Demers C, McKelvie RS, et al. 2002. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol, 39:463-70.
37. Jorde UP, Ennezat PV, Lisker J, et al. 2000. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation, 101:844-6.
38. Jugdutt BI. 1983. Myocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial effect with marked nitroglycerin-induced hypotension. Circulation, 68:673-84.
39. Jugdutt BI. 1991. Intravenous nitroglycerin unloading in acute myocardial infarction. Am J Cardiol, 68:52D-63D.
40. Jugdutt BI. 1993. Prevention of ventricular remodelling post myocardial infarction: timing and duration of therapy. Can J Cardiol, 9:103-14.
41. Jugdutt BI. 1995. Modification of left ventricular remodelling after myocardial infarction. In: Dhalla NS, Beamish RE, Nagano M (eds). The failing heart. New York: Raven Pr. pp 231-45.
42. Jugdutt BI. 1996. Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. Heart Failure Rev, 1:115-29.
43. Jugdutt BI. 1998. Angiotensin II receptor blockers. In: Crawford MH (ed). Cardiology Clinics Annual of Drug Therapy. Philadelphia: WB Saunders Pub, Vol 2, pp 1-17.
44. Jugdutt BI. 2003a. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord, 3:1-30.
45. Jugdutt BI. 2003b. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation, 108:1395-403.
46. 1-receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst, 2:134-40.
47. 2 receptors during reperfused myocardial infarction. Mol and Cell Biochem, 260:111-18.
48. Jugdutt BI, Menon V. 2004b. Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat in vivo models of reperfused myocardial infarction. J Cardiac Failure, 10:74-82.
49. 1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction. Detection using proteomics. Mol and Cell Biochem, 263:179-88.
50. Jugdutt BI, Warnica JW. 1988. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: effect of timing, dosage and infarct location. Circulation, 78:906-19.
51. Jugdutt BI, Warnica JW. 1989. Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction. Am J Cardiol, 64:581-7.
52. ε proteins and cGMP. J Cardiovasc Pharmacol Ther, 5:301-11.
53. Julius S, Kjeldsen SE, Weber M, et al. for the VALUE trial group. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363:2022-31.
54. Kawamura M, Imanashi M, Matsushima Y, et al. 1992. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol, 19:547-53.
55. Kober L, Torp-Pedersen C, Carlsen JE, et al. 1995. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med, 333:1670-6.
56. Langtry HD, McClellan KJ. 1999. Valsartan/hydrochlorothiazide. Drugs, 57:751-5.
57. Latini R, Masson S, Anand I, et al; Valsartan Heart Failure Trial Investigators. 2002. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 106:2454-8.
58. Lee VC, Rhew DC, Dylan M, et al. 2004. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med, 141:693-704.
59. 2 receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. Am J Pathol, 156:1663-72.
60. Levy BI. 2004. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation, 109:8-13.
61. Lisheng L, Liu LS, Wang W, et al; Chinese Cardiac Study Collaborative Group. 1995. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarctio: interim report from the Chinese Cardiac Study (CCS-1). Lancet, 345:686-7.
62. Liu YH, Yang XP, Sharov VG, et al. 1997. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest, 99:1926-35.
63. Loot AE, Roks AJ, Henning RH, et al. 2002. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 105:1548-50.
64. Maggioni AP, Anand I, Gottlieb SO, et al; Val-HeFT Investigators (Valsartan Heart Failure Trial). 2002. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol, 40:1414-21.
65. Maggioni AP, Latini R, Carson PE, et al; Val-HeFT Investigators. 2005. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J, 149:548-57.
66. Markham A, Goa KL. 1997. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs, 54:299-311.
67. McKelvie RS, Yusuf S, Pericak D, et al. 1999. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation, 100:1056-64.
68. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 362:767-71.
69. McMurray J. 2005. Angiotensin receptor blockers and myocardial infarction: Analysis of evidence is incomplete and inaccurate. Rapid response. BMJ, 330:1269.
70. Modena MG, Aveta P, Menozzi A, et al. 2001. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J, 141:41-6.
71. New RB, Sampson AC, King MK, et al. 2000. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance. Circulation, 102:1447-53.
72. O'Connell JB. 2000. The economic burden of heart failure. Clin Cardiol, 23(Suppl III):6-103.
73. Opie LH, Sack MN. 2001. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res, 88:654-8.
74. Pfeffer JM, Pfeffer MA, Braunwald E. 1985. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res, 57:84-95.
75. Pfeffer MA. 1998. ACE inhibitors in acute myocardial infarction: patient selection and timing. Circulation, 97:2192-4.
76. Pfeffer MA, Braunwald E. 1990. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation, 81:1161-72.
77. Pfeffer MA, Braunwald E, Moyé LA, et al; SAVE Investigators. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 327:669-77.
78. Pfeffer MA, Greaves SC, Arnold JM, et al. 1997. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation, 95:2643-51.
79. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. 2003. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 349:1893-906.
80. Pfeffer MA, Swedberg K, Granger CB, et al; CHARM Investigators and Committees. 2003. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362:759-66.
81. Pitt B, Poole-Wilson PA, Segal R, et al. 2000. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet, 355:1582-7.
82. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. 2003. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 348:1309-21.
83. Pitt B, Segal R, Martinez FA, et al. 1997. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 349:747-52.
84. Pitt B, White H, Nicolau J, et al; EPHESUS Investigators. 2005. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol, 46:425-31.
85. Pitt B, Zannad F, Remme WJ, et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 341:709-17.
86. Sawicki G, Jugdutt BI. 2004. Detection of changes in protein levels in the in vivo canine model of acute heart failure following ischemia-reperfusion injury - Functional proteomics studies. Proteomics, 4:2195-202.
87. 1 receptor blockade. J Cardiac Failure, 10:442-9.
88. Seyedi N, Xu X, Nasjletti A, et al. 1995. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension, 26:164-70.
89. Sharpe N. 1999. Benefit of beta-blockers for heart failure: proven in 1999. Lancet, 353:1988-9.
90. Solomon SD, Glynn RJ, Greaves S, et al. 2001. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med, 134:451-8.
91. Solomon SD, Skali H, Anavekar NS, et al. 2005. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation, 111:3411-19.
92. [SOLVD] The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 325:293-302.
93. [SOLVD] The SOLVD Investigators. 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med, 327:685-91.
94. Spinale FG, de Gasparo M, Whitebread S, et al. 1997. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. Circulation, 96:2385-96.
95. St John Sutton M, Pfeffer MA, Plappert T, et al; SAVE Investigators: 1994. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation, 89:68-75.
96. Suzuki G, Morita H, Mishima T, et al. 2002. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation, 106:2967-72.
97. Swedberg K, Held P, Kjekshus J, et al; CONSENSUS Study Group. 1992. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med, 327:678-84.
98. Szummer KE, Solomon SD, Velazquez EJ, et al; VALIANT Registry. 2005. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. Eur Heart J, 26:2114-19.
99. Timmermans PB, Carini DJ, Chiu AT, et al. 1991. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens, 4:275S-81S.
100. Tom B, de Vries R, Saxena PR, et al. 2001. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension, 38:95-9.
101. Urata H, Healy B, Stewart RW, et al. 1990. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res, 66:883-90.
102. Velazquez EJ, Francis GS, Armstrong PW, et al; VALIANT registry. 2004. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J, 25:1911-19.
103. Verdecchia P, Angeli F, Gattobigio R, et al. 2005. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J, 26:2381-6.
104. Verheijen I, Fierens FL, Debacker JP, et al. 2000. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fundam Clin Pharmacol, 14:577-85.
105. Verma S, Strauss M. 2004. Angiotensin receptor blockers and myocardial infarction. BMJ, 329:1248-9.
106. Wellington K, Faulds DM. 2002. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs, 62:1983-2005.
107. Wong M, Johnson G, Shabetai R, et al. 1993. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. Circulation, 87(6 Suppl):VI-65-70.
108. Wong M, Staszewsky L, Latini R, et al. 2004. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol, 43:2022-7.
109. 3 receptor and PKCe proteins. J Renin Angiotensin Aldosterone Syst, 1:184-95.
110. Yu CM, Tipoe GL, Wing-Hon Lai K, et al. 2001. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol, 38:1207-15.
111. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. 2003. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 362:777-81.
112. Yusuf S. 2002. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol, 89(2A):18A-25A.
113. Zannad F, Alla F, Dousset B, et al. 2000. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation, 102:2700-6.